Barron's take
-
Subscriber Content Read Preview
September 30![[image]](https://web-archive.nli.org.il/National_Library/20161130034600im_/http://barrons.wsj.net/public/resources/images/ON-BU193_regene_C_20160829164123.jpg)
Regeneron Bulls Should Keep Eye on the Prize
Weak clinical trial results of a new combo eye therapy are hitting shares. But we spy a buying opportunity.
Recent Barron's Take
-
Subscriber Content Read Preview
September 29![[image]](https://web-archive.nli.org.il/National_Library/20161130034600im_/http://barrons.wsj.net/public/resources/images/ON-BV049_ConAgr_A_20160929134637.jpg)
Food Stocks Are Boring? ConAgra Begs to Differ
With brands including Slim Jim and Hunt’s, ConAgra can stay hot, helped by rising margins and a 2.3% yield.
-
September 28
Subscriber Content Read Preview
Nike on the Run as Rivals Encroach on Its Turf
-
September 27
Subscriber Content Read Preview
AmEx Hikes Dividend; Stock Can Take Charge
-
September 26
Subscriber Content Read Preview
Pfizer Won’t Split and Neither Should Investors
-
September 21
Subscriber Content Read Preview
FedEx Delivers the Goods; Is Bullish for Rest of 2016
-
September 20
Subscriber Content Read Preview
Royal Caribbean Making Waves With Dividend Hike
-
September 19
Subscriber Content Read Preview
GM, With Its Delectable Dividend, Is Priced to Buy
-
September 16
Subscriber Content Read Preview
Oracle: Buy the Dip
-
September 15
Subscriber Content Read Preview
Apple Stock and iPhone 7 Both Look Like Winners
-
September 14
Subscriber Content Read Preview
Macy’s ‘Gets It’ and Stock Can Ring Up a 25% Gain